Selskabsmeddelelser

Changes to the Board of Directors

May 23, 2022

Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, has previously announced its entry into an agreement with KemPharm Denmark A/S to sell substantially all of its assets and business activities (please see company announcement no. 24/2022) and submission of the restructuring proposal to the Danish Maritime and Commercial High Court (the “Court”) and the Company’s known creditors (please see company announcement no. 26/2022). 

Changes to the Board of Directors

Read more

Restructuring Proposal

May 18, 2022

Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces that the enclosed restructuring proposal (the “Restructuring Proposal”) will be submitted to the Danish Maritime and Commercial High Court (the “Court”) and be sent to the Company’s known creditors following the agreement with KemPharm Denmark A/S to sell substantially all of its assets and business activities (the “Assets”), which is conditional upon the approval by the creditors and the affirmation of the Restructuring Proposal by the Court (please see company announcement no. 24/2022).

Restructuring Proposal

Restructuring proposal including appendices

Read more

Updated Financial Calendar for 2022

May 16, 2022

Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces an update to the Company’s financial calendar for the remainder of 2022 following the signing of a binding agreement with KemPharm, Inc. for sale of substantially all of the company’s assets and business activities during the Company’s in-court restructuring proceedings (see company announcement no. 24/2022).

Updated Financial Calendar for 2022

Read more

Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.

May 15, 2022

Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C (NPC), announces today that it has signed an agreement to sell substantially all of the Company’s assets and business activities to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm Inc. (KMPH: NASDAQ, NY). KemPharm is a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system diseases.

Orphazyme AS under In Court Restructuring to sell substantially all of its assets and business activities to KemPharm Inc 0

Read more

Orphazyme announces update on in-court restructuring proceedings

Apr 29, 2022

Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces an update to the in-court restructuring proceedings of the Company (please see company announcement no. 10/2022 and 11/2022).

Orphazyme announces update on in court restructuring proceedings

Read more

Updated Financial Calendar for 2022

Apr 28, 2022

Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces an update to the Company’s Financial Calendar for the remainder of 2022 following the current status of the in-court restructuring proceedings of the Company (please see company announcements no. 10/2022 and 11/2022).

Updated Financial Calendar for 2022

Read more

Statutory restructuring plan adopted by creditors

Apr 7, 2022

Orphazyme A/S in restructuring (ORPHA.CO) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces that today an in-court meeting was held where the statutory restructuring plan as proposed and published by the Company through company announcement no. 15/2022 on March 31, 2022 and company announcement no. 17/2022 on April 4, 2022, was adopted by the Company’s creditors in accordance with section 11 e of the Danish Insolvency Act. No amendments to the restructuring proposal were made at the meeting.

Statutory restructuring plan adopted by creditors

Read more

Updated Financial Calendar for 2022

Apr 6, 2022

Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces an update to the Company’s Financial Calendar for the remainder of 2022.

Updated Financial Calendar for 2022

Read more

Notice received from the Depositary to holders of ADSs regarding termination of Deposit Agreement

Apr 6, 2022

Orphazyme A/S in restructuring (ORPHA.CO) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, has today received a notice from The Bank of New York Mellon, as depositary (the “Depositary”), that a notification has been sent to holders of American Depositary Shares (“ADSs”) evidenced by American Depositary Receipts (“ADRs”) representing deposited common shares of the Company, regarding termination of the Deposit Agreement dated September 28, 2020 among the Company, the Depositary, and Owners and ADR Holders (the “Deposit Agreement”).

Notice received from the Depositary to holders of ADSs regarding termination of Deposit Agreement

Read more

Correction: Proposal for a statutory restructuring plan

Apr 4, 2022

Orphazyme A/S in restructuring (ORPHA.CO) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, today announced that, in respect to company announcement no. 15/2022 dated March 31, 2022, the Company has been made aware of a typographical error in the header of the table included in Appendix 1B regarding the interim set-off balance as of March 11, 2022.

Appendix 1B

Correction Proposal for a statutory restructuring plan

Read more

1 2 3 4